Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Sell

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Sell

C

Arvinas, Inc (ARVN)

Pharmaceutical Preparations

https://www.arvinas.com

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

395 WINCHESTER AVE, 5 SCIENCE PARK
NEW HAVEN, CT

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

09/27/2018

Market Cap

1,703,159,361

Shares Outstanding

55,030,000

Weighted SO

55,025,504

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

CCCC --.--%

GLUE --.--%

NRIX --.--%

FHTX --.--%

RLAY --.--%

STOK --.--%

PLRX --.--%

BDTX --.--%

STTK --.--%

Beta

1.9780

Last Div

0.0000

Range

13.57-53.08

Chg

-0.7900

Avg Vol

889841

Mkt Cap

1703159361

Exch

NASDAQ

Country

US

Phone

203 535 1456

DCF Diff

44.3108

DCF

-18.7108

Div Yield

0.0000

P/S

18.2547

EV Multiple

-4.2229

P/FV

2.9721

Div Yield %

0.0000

P/E

-5.5159

PEG

-0.1997

Payout

0.0000

Current Ratio

3.6195

Quick Ratio

3.6195

Cash Ratio

0.4617

DSO

39.1211

DIO

0.0000

Op Cycle

39.1211

DPO

1234.5588

CCC

-1195.4377

Gross Margin

0.9271

Op Margin

-3.9764

Pretax Margin

-3.4448

Net Margin

-3.4662

Eff Tax Rate

-0.0062

ROA

-0.2527

ROE

-0.5559

ROCE

-0.3979

NI/EBT

1.0062

EBT/EBIT

0.8663

EBIT/Rev

-3.9764

Debt Ratio

0.0016

D/E

0.0035

LT Debt/Cap

0.0012

Total Debt/Cap

0.0035

Int Coverage

-52.2535

CF/Debt

-102.4286

Equity Multi

2.1320

Rec Turnover

9.3300

Pay Turnover

0.2957

Inv Turnover

0.0000

FA Turnover

8.2566

Asset Turnover

0.0729

OCF/Share

-2.9917

FCF/Share

-3.0195

Cash/Share

17.1655

OCF/Sales

-2.3055

FCF/OCF

1.0093

CF Coverage

-102.4286

ST Coverage

-153.6429

CapEx Coverage

-107.5500

Div&CapEx Cov

-107.5500

P/BV

2.9721

P/B

2.9721

P/S

18.2547

P/E

-5.5159

P/FCF

-7.8450

P/OCF

-8.2931

P/CF

-8.2931

PEG

-0.1997

P/S

18.2547

EV Multiple

-4.2229

P/FV

2.9721

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 16, 17:01 Arvinas Appoints Jared Freedberg as General Counsel Zacks Investment Research Jan 01, 09:55 Arvinas, Inc. (ARVN) Just Flashed Golden Cross Signal: Do You Buy? Zacks Investment Research Dec 25, 09:55 Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to Trade Zacks Investment Research Dec 25, 09:55 Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to Trade Zacks Investment Research Dec 25, 09:55 Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to Trade Zacks Investment Research Dec 25, 09:55 Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to Trade Zacks Investment Research Dec 25, 09:55 Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to Trade Zacks Investment Research Dec 25, 09:55 Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to Trade Zacks Investment Research Dec 25, 09:55 Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to Trade Zacks Investment Research Dec 25, 09:55 Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to Trade Zacks Investment Research Dec 25, 09:55 Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to Trade Zacks Investment Research Dec 25, 09:55 Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to Trade Zacks Investment Research Dec 25, 09:55 Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to Trade Zacks Investment Research Dec 25, 09:55 Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to Trade Zacks Investment Research Dec 25, 09:55 Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to Trade Benzinga Dec 06, 14:43 Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session GlobeNewswire Inc. Dec 05, 22:52 Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program GlobeNewswire Inc. Dec 05, 22:52 Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program GlobeNewswire Inc. Dec 05, 22:52 Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program GlobeNewswire Inc. Dec 05, 13:33 Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program

Revenue Product Segmentation